CN107106675A - 疫苗接种 - Google Patents

疫苗接种 Download PDF

Info

Publication number
CN107106675A
CN107106675A CN201580068948.3A CN201580068948A CN107106675A CN 107106675 A CN107106675 A CN 107106675A CN 201580068948 A CN201580068948 A CN 201580068948A CN 107106675 A CN107106675 A CN 107106675A
Authority
CN
China
Prior art keywords
vaccine
immunogenic
composition
years
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580068948.3A
Other languages
English (en)
Chinese (zh)
Inventor
T.C.海涅曼
E.G.C.莱登特
N.P.F.勒克勒尼耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201503266A external-priority patent/GB201503266D0/en
Priority claimed from GBGB1518917.8A external-priority patent/GB201518917D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN107106675A publication Critical patent/CN107106675A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201580068948.3A 2014-12-18 2015-12-16 疫苗接种 Pending CN107106675A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1422686.4 2014-12-18
GB201422686 2014-12-18
GB1503266.7 2015-02-26
GB201503266A GB201503266D0 (en) 2015-02-26 2015-02-26 Vaccination
GB1518917.8 2015-10-26
GBGB1518917.8A GB201518917D0 (en) 2015-10-26 2015-10-26 Vaccination
PCT/EP2015/079967 WO2016096968A1 (en) 2014-12-18 2015-12-16 Vaccination

Publications (1)

Publication Number Publication Date
CN107106675A true CN107106675A (zh) 2017-08-29

Family

ID=54937057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580068948.3A Pending CN107106675A (zh) 2014-12-18 2015-12-16 疫苗接种

Country Status (8)

Country Link
US (1) US20180008700A1 (https=)
EP (1) EP3233118A1 (https=)
JP (1) JP2018500322A (https=)
CN (1) CN107106675A (https=)
BR (1) BR112017012647A2 (https=)
CA (1) CA2970840A1 (https=)
MX (1) MX2017008055A (https=)
WO (1) WO2016096968A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109602901A (zh) * 2019-01-08 2019-04-12 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070601A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
CN108778289B (zh) 2015-11-06 2020-11-17 佐剂技术公司 三萜皂苷类似物
CA3061205A1 (en) 2017-04-25 2018-11-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues
CN110621339A (zh) * 2017-04-28 2019-12-27 葛兰素史密丝克莱恩生物有限公司 疫苗接种
BR112020023642A2 (pt) * 2018-05-23 2021-02-17 Mogam Institute For Biomedical Research variante de antígeno de vírus de varicela zoster e uso da mesma
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
IL292796A (en) * 2019-11-05 2022-07-01 Adjuvance Tech Inc Varicella zoster immunogenic compositions and uses thereof
BR112022017852A2 (pt) 2020-03-09 2022-11-01 Dynavax Tech Corp Vacinas para herpes zoster compreendendo um agonista de tlr9
EP4526327A1 (en) * 2022-05-20 2025-03-26 GlaxoSmithKline Biologicals S.A. Modified varicella zoster virus glycoprotein e proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189254A (zh) * 2005-03-03 2008-05-28 葛兰素史密丝克莱恩生物有限公司 疫苗
CN103405764A (zh) * 2005-12-13 2013-11-27 葛兰素史密丝克莱恩生物有限公司 包含皂苷佐剂的疫苗组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189254A (zh) * 2005-03-03 2008-05-28 葛兰素史密丝克莱恩生物有限公司 疫苗
CN103405764A (zh) * 2005-12-13 2013-11-27 葛兰素史密丝克莱恩生物有限公司 包含皂苷佐剂的疫苗组合物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHLIBEK ROMAN ET AL: "Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >= 50 Years of Age", 《JOURNAL OF INFECTIOUS DISEASES》 *
CHLIBEK ROMAN ET AL: "Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study", 《VACCINE》 *
E. M. BERKOWITZ ET AL: "Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study", 《JOURNAL OF INFECTIOUS DISEASES》 *
HAUMONT M ET AL: "Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells", 《VIRUS RESEARCH》 *
LEROUX-ROELS ISABEL ET AL: "A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults", 《 THE JOURNAL OF INFECTIOUS DISEASES》 *
M.N. OXMAN ET AL: "A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults", 《NEW ENGLAND JOURNAL OF MEDICINE》 *
STADTMAUER EA ET AL: "A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients", 《BLOOD》 *
V. A. MORRISON ET AL: "Long-term Persistence of Zoster Vaccine Efficacy", 《CLINICAL INFECTIOUS DISEASES》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109602901A (zh) * 2019-01-08 2019-04-12 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用

Also Published As

Publication number Publication date
MX2017008055A (es) 2017-09-28
EP3233118A1 (en) 2017-10-25
CA2970840A1 (en) 2016-06-23
BR112017012647A2 (pt) 2018-01-09
US20180008700A1 (en) 2018-01-11
JP2018500322A (ja) 2018-01-11
WO2016096968A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
CN107106675A (zh) 疫苗接种
CA2797937C (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AU2011343368C1 (en) Mycobacterium antigenic composition
US20210187098A1 (en) Vaccination
US20110104260A1 (en) Vaccine against varicella zoster virus
EP3125929B1 (en) Novel methods for inducing an immune response
EP2440243A1 (en) Immunogenic compositions having low sodium chloride concentration
PL215257B1 (pl) Zastosowanie kompozycji zawierajacej VLP HPV 16 i HPV 18 oraz kompozycja szczepionkowa
US9782474B2 (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9624273B2 (en) Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
BE1022523B1 (fr) Vaccination
US20080152671A1 (en) Novel vaccination
Cunningham et al. Herpes Zoster Vaccines: What's New?
TW202436326A (zh) 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170829